- Home
- WDI vs ATXS Comparison
WDI vs ATXS Comparison
Compare WDI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WDI | ATXS |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 788.9M | 676.1M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | WDI | ATXS |
|---|---|---|
| Price | $14.34 | $12.66 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $24.33 |
| AVG Volume (30 Days) | 192.6K | ★ 1.0M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 11.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | N/A | ★ $706,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.16 | $3.56 |
| 52 Week High | $14.69 | $12.72 |
Technical Indicators
Market Signals| Indicator | WDI | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 46.14 | 67.26 |
| Support Level | $14.05 | $12.29 |
| Resistance Level | $14.51 | $12.57 |
| Average True Range (ATR) | 0.16 | 0.20 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 61.96 | 92.50 |
Price Performance
Historical ComparisonAbout WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.